CLPTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ClearPoint Neuro, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$9.17+0.10 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $276.63M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$16.21 (−63.86%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ClearPoint Neuro, Inc. grew revenue 25.9% to $42.28M over the twelve months to Jun 30, 2026. Free cash flow was -$31.27M.
Revenue
$42.28M
+25.9% vs. a year earlier
Operating income
-$31.04M
TTM Q2 2026
Free cash flow
-$31.27M
TTM Q2 2026
EPS, diluted
-$1.18
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $276.63M
- P/E ratio
- –
- Price to sales
- 6.54
- Price to book
- 25.67
- Dividend yield
- –
- Free cash flow yield
- -11.30%
Fundamentals
- Revenue
- $42.28M
- Net income
- -$34.57M
- EPS, diluted
- -$1.18
- Free cash flow
- -$31.27M
- Book value per share
- $0.36
- Diluted shares
- 30M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$42.28M+25.9% YoY
Gross profit
$26.47M+30.4% YoY
Operating income
-$31.04M
Net income
-$34.57M
EPS, diluted
-$1.18
Free cash flow
-$31.27M
Reported periodTrailing twelve months